News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Accentia, Inc.'s CEO Provides Outlook for 2008 including Update on SinuNase Phase 3 Blinded Trial Results on 80% of Patients



1/7/2008 8:31:22 AM

TAMPA, Fla.--(BUSINESS WIRE)--The following letter is from Dr. Francis E. O’Donnell, Jr., Chairman and Chief Executive Officer of Accentia Biopharmaceuticals (NASDAQ:ABPI). In addition to these comments, stockholders and potential investors are referred to: the Company’s SEC filings, including Form 10-K and Form 10-Q (Annual and Quarterly Reports); press releases; website; and other publicly disseminated information, which is available free of charge upon request by contacting the Company.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES